The Trump administration has moved to strip decades-old safety warnings from testosterone therapy labels, clearing a path for millions of ageing American men to reach for a treatment long shadowed by caution.
The US Department of Health and Human Services (HHS) announced on 18 June 2026 that it had asked drugmakers to rewrite the prescribing information for testosterone replacement therapy, pointing to fresh clinical evidence.